Evotec AG and Ono Pharmaceutical Tighten Collaborations
Evotec AG (Hamburg, Germany) has announced it is extending the protease collaboration it forged with Ono Pharmaceutical (Osaka, Japan) back in March 2008 and is entering into a new discovery agreement with the international drug development company. The new agreement targets an ion channel-ion channels are said to be implicated in cardiovascular, neurological, urological, metabolic, andinflammatory diseases.
Under the new agreement, Evotec will receive research funding for 18 months along with success-based milestones based on progress. Ono, meanwhile, is given worldwide rights to develop and market a product containing the compound discovered.
“Since...the existing collaboration with Evotec targeting a protease has progressed as planned, we are now pleased to enter into a new drug discovery agreement on an ion channel with Evotec utilizing their proprietary drug discovery platform," said Ono's Kazuhito Kawabata, PhD, Managing Director, Research Headquarters. "We anticipate the collaboration will result in identifying a novel drug candidate with a high potential.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
